Russian invasion of Ukraine threatens hundreds of clinical trials
Day 2 of the Russian invasion has brought headlines of a battle for the nation’s capital, signs that millions of Ukrainians may become refugees and shortages of food and medicine that threatens everyone in the country.
For biotech analysts, though, their job has centered on the potential disruption around hundreds of ongoing drug trials and the potential implications for the industry, as Ukraine is ripped apart by a bloody war and Russia — which also hosts studies — faces economic sanctions.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.